Evidence map›Paper›PMID 17384219›Full record

ArticleThe Journal of molecular diagnostics : JMD2007

Clinical and analytical sensitivities in hereditary hemorrhagic telangiectasia testing and a report of de novo mutations.

Friederike Gedge, Jamie McDonald, Amit Phansalkar, Lan-Szu Chou, Fernanda Calderon, Rong Mao, Elaine Lyon, Pinar Bayrak-Toydemir

Abstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. AThe Journal of international medical research · 2023
    Article
  6. Article
  7. Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management.Hematology. American Society of Hematology. Education Program · 2021
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Genetic Insights into Cerebrovascular Disorders: A Comprehensive Review.Journal of vascular and interventional neurology · 2017
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Why is genetic screening for autosomal dominant disorders underused in families? The case of hereditary hemorrhagic telangiectasia.Genetics in medicine : official journal of the American College of Medical Genetics · 2011
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Friederike GedgeAssociated Regional and University Pathologists, Institute of Clinical and Experimental Pathology, Salt Lake City, Utah, USA.
Jamie McDonald
Amit Phansalkar
Lan-Szu Chou
Fernanda Calderon
Rong Mao
Elaine Lyon
Pinar Bayrak-Toydemir

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary hemorrhagic telangiectasia is a vascular dysplasia with variable onset and expression. Through identification of a mutation in a proband, mutation testing can be offered to family members. Mutation carriers can receive medical surveillance and treatment before potentially fatal complications arise. In this study, we assessed the significance of clinical evaluations as part of hereditary hemorrhagic telangiectasia diagnostic testing to determine the clinical sensitivity of molecular testing and to report novel mutations. Based on reported clinical symptoms, we classified 142 consecutive cases as affected, suspected, or unlikely affected. We performed temperature gradient capillary electrophoresis and full gene sequencing of both ACVRL1 and ENG genes. We then compared the mutation detection rates between these groups, categorizing sequence variants as mutations, variants of uncertain significance (VUS), or known polymorphisms. Our mutation and VUS detection rate in affected individuals was 74% and 16% in the suspected/unlikely affected group. Sixty-one percent of the mutations and all VUS were novel. The mutation detection rate for temperature gradient capillary electrophoresis was 97%. Our results suggest that a careful clinical evaluation increases the mutation detection rate. We have confirmed the occurrence of de novo mutations in three patients. Our results also show that temperature gradient capillary electrophoresis is an efficient mutation screening method.

Indexed as

DNA Mutational AnalysisElectrophoresis, CapillaryExonsGenetic TestingHumansIntronsMutationPolymorphism, GeneticSensitivity and SpecificityTelangiectasia, Hereditary Hemorrhagic

Identifiers

PMID17384219
PMCPMC1867450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.